Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands

Cellular and Molecular Life Sciences

Volumn 70, Issue 18, 2013, Pages 3243-3275

  Galat, Andrzej ^a  

^a Institute Frederic Joliot   (France)

Author keywords

FK506; FKBP; PPIase; Rapamycin; Sirolimus; Tacrolimus

Indexed keywords

ANTIBIOTIC AGENT; ASCOMYCIN; EVEROLIMUS; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; PIMECROLIMUS; PROTEIN FKBP12; PROTEIN VARIANT; RAPAMYCIN; RIDAFOROLIMUS; TACROLIMUS; TEMSIROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CELL COMMUNICATION; COMPLEX FORMATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; IMMUNOREGULATION; INTRACELLULAR SIGNALING; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; UNINDEXED SEQUENCE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; CELL NUCLEUS; HUMANS; IMMUNOSUPPRESSION; LIGANDS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID; SIROLIMUS; TACROLIMUS BINDING PROTEINS;

EID: 84883448191     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-012-1206-z     Document Type: Review

References (278)

1. Galat A, Riviere S (1998) Peptidyl-prolyl cis/trans isomerases. Protein profile. Oxford University Press, Oxford
2. Harding MW, Galat A, Uehling DE, Schreiber SL (1989) A receptor for the immunosuppressant FK-506 is a cis-trans peptidyl-prolyl isomerase. Nature 341:761-763
3. Siekerka JJ, Hung SHY, Poe M, Lin SC, Sigal NH (1989) A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341:755-757
4. Galat A (2004) A note on clustering the functionally related paralogues and orthologues of proteins: a case of the FK506-binding proteins (FKBPs). Comp Biol Chem 28:129-140
5. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H (1987) FK505, A novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 40:1249-1255
6. Sehgal SN, Baker H, Vezina C (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 28:727-732
7. Eng CP, Sehgal SN, Vezina C (1984) Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 37:1231-1237
8. Hatanaka H, Iwami M, Kino T, Goto T, Okuhara M (1988) FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. I. Taxonomy of the producing strain. J Antibiot (Tokyo) 41:1586-1591
9. Hatanaka H, Kino T, Miyata S, Inamura N, Kuroda A, Goto T, Tanaka H, Okuhara M (1988) FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics. J Antibiot (Tokyo) 41:1592-1601
10. Cai P, Tsao R, Ruppen ME (2007) In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab Dispos 35:1554-1563
11. Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C (2003) Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14:931-937
12. Kirchner GI, Meier-Wiedenbach I, Manns MP (2004) Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43:83-95
13. Chen Q, Zielinski D, Chen J, Nowak S, Zhou CC (2009) Structural identification and characterization of potential degradants of zotarolimus on zotarolimus-coated drug-eluting stents. J Pharm Biomed Anal 50:778-786
14. Kong F, Zhu T, Yu K, Pagano TG, Desai P, Radebaugh G, Fawzi M (2011) Isolation and structure of homotemsirolimuses A, B, and C. J Nat Prod 74:547-553
15. Holt DA, Luengo JL, Yamashita DS, Oh H-J, Konialian AL, Yen H-K, Rozamus LW, Brandt M, Bossard MJ, Levy MA, Eggleston DS, Liang J, Schultz LW, Stout TJ, Clardy J (1993) Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12. J Am Chem Soc 115:9925-9938
16. Blackburn EA, Walkinshaw MD (2011) Targeting FKBP isoforms with small-molecule ligands. Curr Opin Pharmacol 11:365-371
17. 15N NMR relaxation studies of the FK506 binding protein: dynamic effects of ligand binding and implications for calcineurin recognition. Biochemistry 33:4093-4100
18. Connelly PR, Aldape RA, Bruzzese FJ, Chambers SP, Fitzgibbon MJ, Fleming MA, Itoh S, Livingston DJ, Navia MA, Thomson JA, Wilson KP (1994) Enthalpy of hydrogen bond formation in a protein-ligand binding reaction. Proc Natl Acad Sci USA 91:1964-1968
19. Fulton KF, Jackson SE, Buckle AM (2003) Energetic and structural analysis of the role of tryptophan 59 in FKBP12. Biochemistry 42:2364-2372
20. Lundemose AG, Kay JE, Pearce JH (1993) Chlamydia trachomatis Mip-like protein has peptidyl-prolyl cis/trans isomerase activity that is inhibited by FK506 and rapamycin and is implicated in initiation of chlamydial infection. Mol Microbiol 7:777-783
21. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997) Gapped BLAST and Psi-BLAST: a new generation of protein database search programs. Nucl Acids Res 25:3389-3402
22. Wheeler DL, Church DM, Federhen S, Lash AE, Madden TL, Pontius JU, Schuler GD, Schriml LM, Sequeira E, Tatusova TA, Wagner L (2003) Database resources of National Center for Biotechnology. Nucl Acids Res 31:28-33
23. Galat A (2008) Functional drift of sequence attributes in the FK506-binding proteins (FKBPs). J Chem Inf Model 48:1118-1130
24. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23:2947-2948
25. King N, Westbrook MJ, Young SL, Kuo A, Abedin M, Chapman J, Fairclough S, Hellsten U, Isogai Y, Letunic I, Marr M, Pincus D, Putnam N, Rokas A, Wright KJ, Zuzow R, Dirks W, Good M, Goodstein D, Lemons D, Li W, Lyons JB, Morris A, Nichols S, Richter DJ, Salamov A, Sequencing JG, Bork P, Lim WA, Manning G, Miller WT, McGinnis W, Shapiro H, Tjian R, Grigoriev IV, Rokhsar D (2008) The genome of the choanoflagellate Monosiga brevicollis and the origin of metazoans. Nature 451:783-788
26. Srivastava M, Begovic E, Chapman J, Putnam NH, Hellsten U, Kawashima T, Kuo A, Mitros T, Salamov A, Carpenter ML, Signorovitch AY, Moreno MA, Kamm K, Grimwood J, Schmutz J, Shapiro H, Grigoriev IV, Buss LW, Schierwater B, Dellaporta SL, Rokhsar DS (2008) The Trichoplax genome and the nature of placozoans. Nature 454:955-960
27. Chapman JA, Kirkness EF, Simakov O, Hampson SE, Mitros T, Weinmaier T, Rattei T, Balasubramanian PG, Borman J, Busam D, Disbennett K, Pfannkoch C, Sumin N, Sutton GG, Viswanathan LD, Walenz B, Goodstein DM, Hellsten U, Kawashima T, Prochnik SE, Putnam NH, Shu S, Blumberg B, Dana CE, Gee L, Kibler DF, Law L, Lindgens D, Martinez DE, Peng J, Wigge PA, Bertulat B, Guder C, Nakamura Y, Ozbek S, Watanabe H, Khalturin K, Hemmrich G, Franke A, Augustin R, Fraune S, Hayakawa E, Hayakawa S, Hirose M, Hwang JS, Ikeo K, Nishimiya-Fujisawa C, Ogura A, Takahashi T, Steinmetz PR, Zhang X, Aufschnaiter R, Eder MK, Gorny AK, Salvenmoser W, Heimberg AM, Wheeler BM, Peterson KJ, Bottger A, Tischler P, Wolf A, Gojobori T, Remington KA, Strausberg RL, Venter JC, Technau U, Hobmayer B, Bosch TC, Holstein TW, Fujisawa T, Bode HR, David CN, Rokhsar DS, Steele RE (2010) The dynamic genome of Hydra. Nature 464:592-596
28. Putnam NH, Srivastava M, Hellsten U, Dirks B, Chapman J, Salamov A, Terry A, Shapiro H, Lindquist E, Kapitonov VV, Jurka J, Genikhovich G, Grigoriev IV, Lucas SM, Steele RE, Finnerty JR, Technau U, Martindale MQ, Rokhsar DS (2007) Sea anemone genome reveals ancestral eumetazoan gene repertoire and genomic organization. Science 317:86-94
29. Dehal P, Satou Y, Campbell RK, Chapman J, Degnan B, De Tomaso A, Davidson B, Di Gregorio A, Gelpke M, Goodstein DM, Harafuji N, Hastings KE, Ho I, Hotta K, Huang W, Kawashima T, Lemaire P, Martinez D, Meinertzhagen IA, Necula S, Nonaka M, Putnam N, Rash S, Saiga H, Satake M, Terry A, Yamada L, Wang HG, Awazu S, Azumi K, Boore J, Branno M, Chin-Bow S, DeSantis R, Doyle S, Francino P, Keys DN, Haga S, Hayashi H, Hino K, Imai KS, Inaba K, Kano S, Kobayashi K, Kobayashi M, Lee BI, Makabe KW, Manohar C, Matassi G, Medina M, Mochizuki Y, Mount S, Morishita T, Miura S, Nakayama A, Nishizaka S, Nomoto H, Ohta F, Oishi K, Rigoutsos I, Sano M, Sasaki A, Sasakura Y, Shoguchi E, Shin-i T, Spagnuolo A, Stainier D, Suzuki MM, Tassy O, Takatori N, Tokuoka M, Yagi K, Yoshizaki F, Wada S, Zhang C, Hyatt PD, Larimer F, Detter C, Doggett N, Glavina T, Hawkins T, Richardson P, Lucas S, Kohara Y, Levine M, Satoh N, Rokhsar DS (2002) The draft genome of Ciona intestinalis: insights into chordate and vertebrate origins. Science 298:2157-2167
30. Putnam NH, Butts T, Ferrier DE, Furlong RF, Hellsten U, Kawashima T, Robinson-Rechavi M, Shoguchi E, Terry A, Yu JK, Benito-Gutiérrez EL, Dubchak I, Garcia-Fernandez J, Gibson-Brown JJ, Grigoriev IV, Horton AC, de Jong PJ, Jurka J, Kapitonov VV, Kohara Y, Kuroki Y, Lindquist E, Lucas S, Osoegawa K, Pennacchio LA, Salamov AA, Satou Y, Sauka-Spengler T, Schmutz J, Shin-I T, Toyoda A, Bronner-Fraser M, Fujiyama A, Holland LZ, Holland PW, Satoh N, Rokhsar DS (2008) The amphioxus genome and the evolution of the chordate karyotype. Nature 453:1064-1071
31. Sodergren E, Weinstock GM, Davidson EH, Cameron RA, Gibbs RA, Angerer RC, Angerer LM, Arnone MI, Burgess DR, Burke RD, Coffman JA, Dean M, Elphick MR, Ettensohn CA, Foltz KR, Hamdoun A, Hynes RO, Klein WH, Marzluff W, McClay DR, Morris RL, Mushegian A, Rast JP, Smith LC, Thorndyke MC, Vacquier VD, Wessel GM, Wray G, Zhang L, Elsik CG, Ermolaeva O, Hlavina W, Hofmann G, Kitts P, Landrum MJ, Mackey AJ, Maglott D, Panopoulou G, Poustka AJ, Pruitt K, Sapojnikov V, Song X, Souvorov A, Solovyev V, Wei Z, Whittaker CA, Worley K, Durbin KJ, Shen Y, Fedrigo O, Garfield D, Haygood R, Primus A, Satija R, Severson T, Gonzalez-Garay ML, Jackson AR, Milosavljevic A, Tong M, Killian CE, Livingston BT, Wilt FH, Adams N, Bellé R, Carbonneau S, Cheung R, Cormier P, Cosson B, Croce J, Fernandez-Guerra A, Genevière AM, Goel M, Kelkar H, Morales J, Mulner-Lorillon O, Robertson AJ, Goldstone JV, Cole B, Epel D, Gold B, Hahn ME, Howard-Ashby M, Scally M, Stegeman JJ, Allgood EL, Cool J, Judkins KM, McCafferty SS, Musante AM, Obar RA, Rawson AP, Rossetti BJ, Gibbons IR, Hoffman MP, Leone A, Istrail S, Materna SC, Samanta MP, Stolc V, Tongprasit W, Tu Q, Bergeron KF, Brandhorst BP, Whittle J, Berney K, Bottjer DJ, Calestani C, Peterson K, Chow E, Yuan QA, Elhaik E, Graur D, Reese JT, Bosdet I, Heesun S, Marra MA, Schein J, Anderson MK, Brockton V, Buckley KM, Cohen AH, Fugmann SD, Hibino T, Loza-Coll M, Majeske AJ, Messier C, Nair SV, Pancer Z, Terwilliger DP, Agca C, Arboleda E, Chen N, Churcher AM, Hallbook F, Humphrey GW, Idris MM, Kiyama T, Liang S, Mellott D, Mu X, Murray G, Olinski RP, Raible F, Rowe M, Taylor JS, Tessmar-Raible K, Wang D, Wilson KH, Yaguchi S, Gaasterland T, Galindo BE, Gunaratne HJ, Juliano C, Kinukawa M, Moy GW, Neill AT, Nomura M, Raisch M, Reade A, Roux MM, Song JL, Su YH, Townley IK, Voronina E, Wong JL, Amore G, Branno M, Brown ER, Cavalieri V, Duboc V, Duloquin L, Flytzanis C, Gache C, Lapraz F, Lepage T, Locascio A, Martinez P, Matassi G, Matranga V, Range R, Rizzo F, Rottinger E, Beane W, Bradham C, Byrum C, Glenn T, Hussain S, Manning G, Miranda E, Thomason R, Walton K, Wikramanayke A, Wu SY, Xu R, Brown CT, Chen L, Gray RF, Lee PY, Nam J, Oliveri P, Smith J, Muzny D, Bell S, Chacko J, Cree A, Curry S, Davis C, Dinh H, Dugan-Rocha S, Fowler J, Gill R, Hamilton C, Hernandez J, Hines S, Hume J, Jackson L, Jolivet A, Kovar C, Lee S, Lewis L, Miner G, Morgan M, Nazareth LV, Okwuonu G, Parker D, Pu LL, Thorn R, Wright R (2006) The genome of the sea urchin Strongylocentrotus purpuratus. Science 314:941-952
32. Rokas A, Williams BL, King N, Carroll SB (2003) Genome-scale approaches to resolving incongruence in molecular phylogenies. Nature 425:798-804
33. Viklund IM, Aspenstrom P, Meas-Yedid V, Zhang B, Kopec J, Agren D, Schneider G, D'Amato M, Olivo-Marin JC, Sansonetti P, Van Nhieu GT, Pettersson S (2009) WAFL, a new protein involved in regulation of early endocytic transport at the intersection of actin and microtubule dynamics. Exp Cell Res 315:1040-1052
34. Galat A (2000) Sequence diversification of the FK506-binding proteins in several different genomes. Eur J Biochem 267:4945-4959
35. Galat A, Bua J (2010) Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci 67:3467-3488
36. Gopalan G, He Z, Battaile KP, Luan S, Swaminathan K (2006) Structural comparison of oxidized and reduced FKBP13 from Arabidopsis thaliana. Proteins 65:789-795
37. Pemberton TJ (2006) Identification and comparative analysis of sixteen fungal peptidyl-prolyl cis/trans isomerase repertoires. BMC Genomics 7:244
38. Richardson JM, Dornan J, Opamawutthikul M, Bruce S, Page AP, Walkinshaw MD (2007) Cloning, expression and characterization of FKB-6, the sole large TPR-containing immunophilin from C. elegans. Biochem Biophys Res Commun 360:566-572
39. Nakajima O, Nakamura F, Yamashita N, Tomita Y, Suto F, Okada T, Iwamatsu A, Kondo E, Fujisawa H, Takei K, Goshima Y (2006) FKBP133: a novel mouse FK506-binding protein homolog alters growth cone morphology. Biochem Biophys Res Commun 346:140-149
40. Kuzuhara T, Horikoshi M (2004) A nuclear FK506-binding protein is a histone chaperone regulating rDNA silencing. Nat Struct Mol Biol 11:275-283
41. Nelson CJ, Santos-Rosa H, Kouzarides T (2006) Proline isomerization of histone H3 regulates lysine methylation and gene expression. Cell 126:905-916
42. Macqueen AJ, Roeder GS (2009) Fpr3 and Zip3 ensure that initiation of meiotic recombination precedes chromosome synapsis in budding yeast. Curr Biol 19:1519-1526
43. Hochwagen A, Tham WH, Brar GA, Amon A (2005) The FK506 binding protein Fpr3 counteracts protein phosphatase 1 to maintain meiotic recombination checkpoint activity. Cell 122:861-873
44. Padmanabhan N, Fichtner L, Dickmanns A, Ficner R, Schulz JB, Braus GH (2009) The yeast HtrA orthologue Ynm3 is a protease with chaperone activity that aids survival under heat stress. Mol Biol Cell 20:68-77
45. Mas C, Guimiot-Maloum I, Guimiot F, Khelfaoui M, Nepote V, Bourgeois F, Boda B, Levacher B, Galat A, Moalic JM, Simonneau M (2005) Molecular cloning and expression pattern of the FKBP25 gene during cerebral cortical neurogenesis. Gene Expr Patterns 5:577-585
46. Cornette JL, Cease KB, Margalit H, Spouge JL, Berzofsky JA, DeLisi C (1987) Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins. J Mol Biol 195:659-685
47. Smith DF (2004) Tetratricopeptide repeat cochaperones in steroid receptor complexes. Cell Stress Chaperones 9:109-121
48. Galat A (2009) On transversal hydrophobicity of some proteins and their modules. J Chem Inf Model 49:1821-1830
49. Galat A (2006) Involvement of some large immunophilins and their ligands in the protection and regeneration of neurons: a hypothetical mode of action. Comput Biol Chem 30:348-359
50. Sinkins WG, Goel M, Estacion M, Schilling WP (2004) Association of immunophilins with mammalian TRPC channels. J Biol Chem 279:34521-34529
51. 2+ channel TRPV5. Am J Physiol Renal Physiol 290:F1253-F1259
52. Taylor P, Dornan J, Carrello A, Minchin RF, Ratajczak T, Walkinshaw MD (2001) Two structures of cyclophilin 40: folding and fidelity of the TPR domains. Structure 9:431-438
53. Granzin J, Eckhoff A, Weiergraber OH (2006) Crystal structure of a multi-domain immunophilin from Arabidopsis thaliana: a paradigm for regulation of plant ABC transporters. J Mol Biol 364:799-809
54. Nakagawa T, Shirane M, Iemura SI, Natsuame T, Nakayama KI (2007) Anchoring the 26S proteasome to the organellar membrane by FKBP38. Genes Cells 12:709-719
55. van Duyne GD, Standaert RF, Karplus PA, Schreiber SLS, Clardy J (1993) Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J Mol Biol 229:105-124
56. Griffith JP, Kim JL, Kim EE, Sintchak MD, Thomson JA, Fitzgibbon JM, Fleming MA, Caron PR, Hsiao K, Navia MA (1995) X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82:507-522
57. Kissinger CR, Parge HE, Knighton DR, Lewis CT, Pelletier LA, Tempczyk A, Kalish VJ, Tucker KD, Showalter RE, Moomaw EW, Gastinel LN, Habuka N, Chen X, Maldonaldo F, Barker JE, Bacquet R, Villafranca JE (1995) Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 378:641-644
58. Choi J, Chen J, Schreiber SL, Clardy J (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273:239-242
59. Huse M, Chen YG, Massagué J, Kuriyan J (1999) Crystal structure of the cytoplasmic domain of the type I TGFβ receptor in complex with FKBP12. Cell 96:425-436
60. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massagué J (2001) The TGFβ receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell 8:671-682
61. Wu B, Li R, Liu Y, Lou Z, Ding Y, Shu C, Ye S, Bartlam M, Shen B, Rao Z (2004) 3D structure of human FK506-binding protein 52: implications for the assembly of the glucocorticoid receptor/Hsp90/immunophilin heterocomplex. Proc Natl Acad Sci USA 101:8348-8353
62. Sinars C, Cheung-Flynn J, Rimerman RA, Scammell JG, Smith DF, Clardy J (2003) Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complex. Proc Natl Acad Sci USA 100:868-873
63. Bracher A, Kozany C, Thost AK, Hausch F (2011) Structural characterization of the PPIase domain of FKBP51, a cochaperone of human Hsp90. Acta Crystallogr D Biol Crystallogr 67:549-559
64. DeLano WL (2002) The PyMOL Molecular Graphics System. San Carlos, CA, USA, DeLano Scientific, http://www://pymol.sourceforge.net/
65. Galat A (2011) Common structural traits for cystine knot domain of the TGFβ superfamily of proteins and three-fingered ectodomain of their cellular receptors. Cell Mol Life Sci 68:3437-3451
66. Albers MW, Walsh CT, Schreiber SL (1990) Substrate specificity for the human rotamase FKBP: a view of FK506 and rapamycin as leucine-(twisted amide)-proline mimics. J Org Chem 55:4984-4986
67. Dolinski K, Muir S, Cardenas M, Heitman J (1997) All cyclophilins and FK506 binding proteins are, individually and collectively, dispensable for viability in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 94:13093-13098
68. Fair K, Anderson M, Bulanova E, Mi H, Tropschug M, Diaz MO (2001) Protein interactions of the MLL PHD fingers modulate MLL target gene regulation in human cells. Mol Cell Biol 21:3589-3597
69. Wang Z, Song J, Milne TA, Wang GG, Li H, Allis CD, Patel DJ (2010) Pro Isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell 141:1183-1194
70. Goodey NM, Benkovic SJ (2008) Allosteric regulation and catalysis emerge via a common route. Nat Chem Biol 4:474-482
71. Kuriyan J, Eisenberg D (2007) The origin of protein interactions and allostery in colocalization. Nature 450:983-990
72. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815
73. Sigal NH, Dumont F (1992) Cyclosporin A, FK506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann Rev Immunol 10:519-560
74. Fruman DA, Klee CB, Bierer BE, Burakoff SJ (1992) Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 89:3686-3690
75. Liu J, Albers MW, Wandless TJ, Luan S, Alberg DG, Belshaw PJ, Cohen P, MacKintosh C, Klee CB, Schreiber SL (1992) Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 31:3896-3901
76. Shlomchik WD (2007) Graft-versus-host disease. Nat Rev Immunol 7:340-352
77. Li L, Xie T (2005) Stem cell niche: structure and function. Annu Rev Cell Dev Biol 21:605-631
78. Stroud JC, Chen L (2003) Structure of NFAT bound to DNA as a monomer. J Mol Biol 334:1009-1022
79. Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905-909
80. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369:756-758
81. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78:35-43
82. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT (1995) Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270:815-822
83. Koltin Y, Faucette L, Bergsma DJ, Levy MA, Cafferkey R, Koser PL, Johnson RK, Livi GP (1991) Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol Cell Biol 11:1718-1723
84. Cafferkey R, Young PR, McLaughlin MM, Bergsma DJ, Koltin Y, Sathe GM, Faucette L, Eng WK, Johnson RK, Livi GP (1993) Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol 13:6012-6023
85. Zagaroza D, Ghavidel A, Heitman J, Schultz MC (1998) Rapamycin induces the Go program of transcriptional repression in yeast by interfering with the TOR signaling pathway. Mol Cell Biol 18:4463-4470
86. Kontoyiannis DP, Lewis RE, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, Del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Albert ND, Wagener MM, Singh N (2008) Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 52:735-738
87. Odom A, Del Poeta M, Perfect J, Heitman J (1997) The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother 41:156-161
88. Reedy JL, Filler SG, Heitman J (2010) Elucidating the Candida albicans calcineurin signaling cascade controlling stress response and virulence. Fungal Genet Biol 47:107-116
89. Wu H, Peisley A, Graef IA, Crabtree GR (2007) NFAT signaling and the invention of vertebrates. Trends Cell Biol 17:251-260
90. Ma Y, Jiang W, Liu Q, Ryuko S, Kuno T (2011) Genome-wide screening for genes associated with FK506 sensitivity in fission yeast. PLoS One 6:e23422
91. Weisman R, Roitburg I, Nahari T, Kupiec M (2005) Regulation of leucine uptake by tor1+ in Schizosaccharomyces pombe is sensitive to rapamycin. Genetics 169:539-550
92. Weisman R (2004) The fission yeast TOR proteins and the rapamycin response: an unexpected tale. Curr Top Microbiol Immunol 279:85-95
93. Ahearn IM, Tsai FD, Court H, Zhou M, Jennings BC, Ahmed M, Fehrenbacher N, Linder ME, Philips MR (2011) FKBP12 binds to acylated H-ras and promotes depalmitoylation. Mol Cell 41:173-185
94. Shou W, Aghdasi B, Armstrong DL, Guo Q, Bao S, Charng MJ, Mathews LM, Schneider MD, Hamilton SL, Matzuk MM (1998) Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 391:489-492
95. Tang W, Ingalls CP, Durham WJ, Snider J, Reid MB, Wu G, Matzuk MM, Hamilton SL (2004) Altered excitation-contraction coupling with skeletal muscle specific FKBP12 deficiency. FASEB J 18:1597-1599
96. Chen Z, Li Z, Wei B, Yin W, Xu T, Kotlikoff MI, Ji G (2010) FKBP12.6-knockout mice display hyperinsulinemia and resistance to high-fat diet-induced hyperglycemia. FASEB J 24:357-363
97. Noguchi N, Yoshikawa T, Ikeda T, Takahashi I, Shervani NJ, Uruno A, Yamauchi A, Nata K, Takasawa S, Okamoto H, Sugawara A (2008) FKBP12.6 disruption impairs glucose-induced insulin secretion. Biochem Biophys Res Commun 371:735-740
98. Li N, Wang T, Wang W, Cutler MJ, Wang Q, Voigt N, Rosenbaum DS, Dobrev D, Wehrens XH (2012) Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knockout mice. Circ Res 110:465-470
99. Wang T, Donahoe PK, Zervos AS (1994) Specific interaction of type I receptors of the TGFβ family with the immunophilin FKBP12. Science 265:674-676
100. Chen YG, Liu F, Massagué J (1997) Mechanism of TGFβ receptor inhibition by FKBP12. EMBO J 16:3866-3876
101. Richards GS, Degnan BM (2009) The dawn of developmental signaling in the metazoa. Cold Spring Harb Symp Quant Biol 74:81-90
102. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA (2011) Latent TGFβ structure and activation. Nature 474:343-349
103. Akool el-S, Doller A, Babelova A, Tsalastra W, Moreth K, Schaefer L, Pfeilschifter J, Eberhardt W (2008) Molecular mechanisms of TGFβ receptor-triggered signaling cascades rapidly induced by the calcineurin inhibitors cyclosporin A and FK506. J Immunol 181:2831-2845
104. Osman B, Doller A, Akool el-S, Holdener M, Hintermann E, Pfeilschifter J, Eberhardt W (2009) Rapamycin induces the TGFβ1/Smad signaling cascade in renal mesangial cells upstream of mTOR. Cell Signal 21:1806-1817
105. Chang H, Brown CW, Matzuk MM (2002) Genetic analysis of the mammalian transforming growth factor-β superfamily. Endocr Rev 23:787-823
106. Nguyen DX, Bos PD, Massagué J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274-284
107. Lanner JT, Georgiou DK, Joshi AD, Hamilton SL (2010) Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol 2:a003996
108. Cameron AM, Nucifora FC Jr, Fung ET, Livingston DJ, Aldape RA, Ross CA, Snyder SH (1997) FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain. J Biol Chem 272:27582-27588
109. Galat A, Lane WS, Standaert RF, Schreiber SL (1992) A rapamycin-selective 25-kDa immunophilin. Biochemistry 31:2427-2434
110. Rivière S, Ménez A, Galat A (1993) On the localization of FKBP25 in T-lymphocytes. FEBS Lett 315:247-251
111. Jin YJ, Burakoff SJ (1993) The 25-kDa FK506-binding protein is localized in the nucleus and associates with casein kinase II and nucleolin. Proc Natl Acad Sci USA 90:7769-7773
112. Leclercq M, Vinci F, Galat A (2000) Mammalian FKBP25 and its associated proteins. Arch Biochem Biophys 380:20-28
113. Yang WM, Yao YL, Seto E (2001) The FK506-binding protein 25 functionally associates with histone deacetylases and with transcription factor, YY1. EMBO J 20:4814-4825
114. Yao YL, Yang WM (2003) The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J Biol Chem 278:42560-42568
115. Ochocka AM, Kampanis P, Nicol S, Allende-Vega N, Cox M, Marcar L, Milne D, Fuller-Pace F, Meek D (2009) FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53. FEBS Lett 583:621-626
116. Andersen JS, Wilkinson CJ, Mayor T, Mortensen P, Nigg EA, Mann M (2003) Proteomic characterization of the human centrosome by protein correlation profiling. Nature 426:570-574
117. Elvira G, Wasiak S, Blandford V, Tong XK, Serrano A, Fan X, del Rayo Sanchez-Carbente M, Servant F, Bell AW, Boismenu D, Lacaille JC, McPherson PS, DesGroseillers L, Sossin WS (2006) Characterization of an RNA granule from developing brain. Mol Cell Proteomics 5:635-651
118. Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR (2005) Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 96:2907-2912
119. Uranishi M, Iida S, Sanda T, Ishida T, Tajima E, Ito M, Komatsu H, Inagaki H, Ueda R (2005) Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy. Leukemia 19:1471-1478
120. Winter AD, Eschenlauer SC, McCormack G, Page AP (2007) Loss of secretory pathway FK506-binding proteins results in cold-sensitive lethality and associate extracellular matrix defects in the nematode Caenorhabditis elegans. J Biol Chem 282:12813-12821
121. Fasseas MK, Dimou M, Katinakis P (2012) The Caenorhabditis elegans parvulin gene subfamily and their expression under cold or heat stress along with the fkb subfamily. Biochem Biophys Res Commun 423:520-525
122. Rulten SL, Kinloch RA, Tateossian H, Robinson C, Gettins L, Kay JE (2006) The human FK506-binding proteins: characterization of human FKBP19. Mamm Genome 17:322-331
123. Wang Y, Han R, Wu D, Li J, Chen C, Ma H, Mi H (2007) The binding of FKBP23 to BiP modulates BiP's ATPase activity with its PPIase activity. Biochem Biophys Res Commun 354:315-320
124. Baumann M, Giunta C, Krabichler B, Ruschendorf F, Zoppi N, Colombi M, Bittner RE, Quijano-Roy S, Muntoni F, Cirak S, Schreiber G, Zou Y, Hu Y, Romero NB, Carlier RY, Amberger A, Deutschmann A, Straub V, Rohrbach M, Steinmann B, Rostasy K, Karall D, Bonnemann CG, Zschocke J, Fauth C (2012) Mutations in FKBP14 cause a variant of Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss. Am J Hum Genet 90:201-216
125. Jo D, Lyu MS, Cho EG, Park D, Kozak CA, Kim MG (2001) Identification and genetic mapping of the mouse Fkbp9 gene encoding a new member of FK506-binding protein family. Mol Cells 12:272-275
126. Patterson CE, Gao J, Rooney AP, Davis EC (2002) Genomic organization of mouse and human 65-kDa FK506-binding protein genes and evolution of the FKBP multigene family. Genomics 79:881-889
127. Ishikawa Y, Vranka J, Wirz J, Nagata K, Bachinger HP (2008) The rough endoplasmic reticulum-resident FK506-binding protein FKBP65 is a molecular chaperone that interacts with collagens. J Biol Chem 283:31584-31590
128. Patterson CE, Abrams WR, Wolter NE, Rosenbloom J, Davis EC (2005) Developmental regulation and coordinate reexpression of FKBP65 with extracellular matrix proteins after lung injury suggest a specialized function for this endoplasmic reticulum immunophilin. Cell Stress Chaperones 10:285-295
129. Unger T, Dym O, Albeck S, Jacobovitch Y, Bernehim R, Marom D, Pisanty O, Breiman A (2010) Crystal structure of the three FK506 binding protein domains of wheat FKBP73: evidence for a unique wFK73-2 domain. J Struct Funct Genomics 11:113-123
130. Shaheen R, Al-Owain M, Faqeih E, Al-Hashmi N, Awaji A, Al-Zayed Z, Alkuraya FS (2011) Mutations in FKBP10 cause both Bruck syndrome and isolated osteogenesis imperfecta in humans. Am J Med Genet A 155A:1448-1452
131. Kelley BP, Malfait F, Bonafe L, Baldridge D, Homan E, Symoens S, Willaert A, Elcioglu N, Van Maldergem L, Verellen-Dumoulin C, Gillerot Y, Napierala D, Krakow D, Beighton P, Superti-Furga A, De Paepe A, Lee B (2011) Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome. J Bone Miner Res 26:666-672
132. van Dijk FS, Nesbitt IM, Zwikstra EH, Nikkels PG, Piersma SR, Fratantoni SA, Jimenez CR, Huizer M, Morsman AC, Cobben JM, van Roij MH, Elting MW, Verbeke JI, Wijnaendts LC, Shaw NJ, Hagler W, McKeown C, Sistermans EA, Dalton A, Meijers-Heijboer H, Pals G (2009) PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet 85:521-527
133. Meng X, Lu X, Morris CA, Keating MT (1998) A novel human gene FKBP6 is deleted in Williams syndrome. Genomics 52:130-137
134. Noguchi J, Ozawa M, Nakai M, Somfai T, Kikuchi K, Kaneko H, Kunieda T (2008) Affected homologous chromosome pairing and phosphorylation of testis specific histone, H2AX, in male meiosis under FKBP6 deficiency. J Reprod Dev 54:203-207
135. Shirane M, Nakayama KI (2003) Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol 5:28-37
136. Choi BH, Yoon HS (2011) FKBP38-Bcl-2 interaction: a novel link to chemoresistance. Curr Opin Pharmacol 11:354-359
137. Bulgakov OV, Eggenschwiler JT, Hong DH, Anderson KV, Li T (2004) FKBP8 is a negative regulator of mouse sonic hedgehog signalling in neural tissues. Development 131:2149-2159
138. Rosner M, Hofer K, Kubista M, Hengstschlager M (2003) Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38. Oncogene 22:4786-4798
139. Wong RLY, Wlodarczyk BJ, Min KS, Scott ML, Kartiko S, Yu W, Merriweather MY, Vogel P, Zambrowicz BP, Finnell RH (2008) Mouse Fkbp8 activity is required to inhibit cell death and establish dorso-ventral patterning in the posterior neural tube. Hum Mol Genet 17:587-601
140. Denny WB, Prapapanich V, Smith DF, Scammell JG (2005) Structure-function analysis of squirrel monkey FK506-binding protein 51, a potent inhibitor of glucocorticoid receptor activity. Endocrinology 146:3194-3201
141. Storer CL, Dickey CA, Galigniana MD, Rein T, Cox MB (2011) FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol Metab 22:481-489
142. Radanyi C, Chambraud B, Baulieu E-E (1994) The ability of the immunophilin FKBP59-HBI to interact with the 90-kDa heat shock protein is encoded by its tetratricopeptide repeat domain. Proc Natl Acad Sci USA 91:11197-11201
143. Heitzer MD, Wolf IM, Sanchez ER, Witchel SF, DeFranco DB (2007) Glucocorticoid receptor physiology. Rev Endocr Metab Disord 8:321-330
144. Hirota Y, Tranguch S, Daikoku T, Hasegawa A, Osuga Y, Taketani Y, Dey SK (2008) Deficiency of immunophilin FKBP52 promotes endometriosis. Am J Pathol 173:1747-1757
145. Chambraud B, Belabes H, Fontaine-Lenoir V, Fellous A, Baulieu EE (2007) The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation. FASEB J 21:2787-2797
146. Hirota Y, Burnum KE, Acar N, Rabinovich GA, Daikoku T, Dey SK (2012) Galectin-1 markedly reduces the incidence of resorptions in mice missing immunophilin FKBP52. Endocrinology 153:2486-2493
147. Attwood BK, Bourgognon J-M, Patel S, Mucha M, Schiavon E, Skrzypiec A, Young KW, Shiosaka S, Korostynski M, Piechota M, Przewlocki R, Pawlak R (2011) Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature 473:372-375
148. Chambraud B, Sardin E, Giustiniani J, Dounane O, Schumacher M, Goedert M, Baulieu EE (2010) A role for FKBP52 in Tau protein function. Proc Natl Acad Sci USA 107:2658-2663
149. Hirota Y, Acar N, Tranguch S, Burnum KE, Xie H, Kodama A, Osuga Y, Ustunel I, Friedman DB, Caprioli RM, Daikoku T, Dey SK (2010) Uterine FK506-binding protein 52 (FKBP52)-peroxiredoxin-6 (PRDX6) signaling protects pregnancy from overt oxidative stress. Proc Natl Acad Sci USA 107:15577-15582
150. Chen H, Yong W, Hinds TD, Yang Z, Zhou Y, Sanchez ER, Shou W (2010) Fkbp52 regulates androgen receptor transactivation activity and male urethra morphogenesis. J Biol Chem 285:27776-27784
151. Tranguch S, Cheung-Flynn J, Daikoku T, Prapapanich V, Cox MB, Xie H, Wang H, Das SK, Smith DF, Dey SK (2005) Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. Proc Nat Acad Sci USA 102:14326-14331
152. Tranguch S, Wang H, Daikoku T, Xie H, Smith DF, Dey SK (2007) FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. J Clin Invest 117:1824-1834
153. Wolf IM, Periyasamy S, Hinds T Jr, Yong W, Shou W, Sanchez ER (2009) Targeted ablation reveals a novel role of FKBP52 in gene-specific regulation of glucocorticoid receptor transcriptional activity. J Steroid Biochem Mol Biol 113:36-45
154. Carver LA, LaPress JJ, Jain S, Dunham EE, Bradfield CA (1998) Characterization of the Ah receptor-associated protein, ARA9. J Biol Chem 273:33580-33587
155. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerod A, Oslo Breast Cancer Consortium (OSBREAC), Lee MT, Shen CY, Tee BT, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van 't Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SA, Salomon AV, Borresen-Dale AL, Richardson AL, Campbell PJ, Futreal PA, Stratton MR (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400-404
156. Discher DE, Mooney DJ, Zandstra PW (2009) Growth factors, matrices, and forces combine and control stem cells. Science 324:1673-1677
157. Campbell PJ (2012) Telomeres and cancer: from crisis to stability to crisis to stability. Cell 148:633-635
158. Yap TA, Workman P (2012) Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 52:549-573
159. Sohocki MM, Bowne SJ, Sullivan LS, Blackshaw S, Cepko CL, Payne AM, Bhattacharya SS, Khaliq S, Qasim MS, Birch DG, Harrison WR, Elder FF, Heckenlively JR, Daiger SP (2000) Mutations in a new photoreceptor-pineal gene on 17p cause Leber congenital amaurosis. Nat Genet 24:79-83
160. Sunnotel O, Hiripi L, Lagan K, McDaid JR, De Leon JM, Miyagawa Y, Crowe H, Kaluskar S, Ward M, Scullion C, Campbell A, Downes CS, Hirst D, Barton D, Mocanu E, Tsujimura A, Cox MB, Robson T, Walsh CP (2010) Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control study. Reprod Biol Endocrinol 8(8):22
161. McKeen HD, Brennan DJ, Hegarty S, Lanigan F, Jirstrom K, Byrne C, Yakkundi A, McCarthy HO, Gallagher WM, Robson T (2011) The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL. Biochem Soc Trans 39:663-668
162. McKeen HD, McAlpine K, Valentine A, Quinn DJ, McClelland K, Byrne C, O'Rourke M, Young S, Scott CJ, McCarthy HO, Hirst DG, Robson T (2008) A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling. Endocrinology 149:5724-5734
163. McKeen HD, Byrne C, Jithesh PV, Donley C, Valentine A, Yakkundi A, O'Rourke M, Swanton C, McCarthy HO, Hirst DG, Robson T (2010) FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy. Cancer Res 70:1090-1100
164. Pan YF, Viklund IM, Tsai HH, Pettersson S, Maruyama IN (2010) The ulcerative colitis marker protein WAFL interacts with accessory proteins in endocytosis. Int J Biol Sci 6:163-171
165. Berman HM, Henrick K, Nakamura H, Markley JL (2007) The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB data. Nucleic Acids Res 35:D301-D303
166. Gold BG, Densmore V, Shou W, Matzuk MM, Gordon HS (1999) Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J Pharmacol Exp Ther 289:1202-1210
167. Bram RJ, Hung DT, Martin PK, Schreiber SL, Crabtree GR (1993) Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 13:4760-4769
168. Friedman J, Weissman I (1991) Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA. Cell 66:799-806
169. Zhang BW, Zimmer G, Chen J, Ladd D, Li E, Alt FW, Wiederrecht G, Cryan J, O'Neill EA, Seidman CE, Abbas AK, Seidman JG (1996) T cell responses in calcineurin Aα-deficient mice. J Exp Med 183:413-420
170. Mukai H, Kuno T, Chang CD, Lane B, Luly JR, Tanaka C (1993) FKBP12-FK506 complex inhibits phosphatase activity of two mammalian isoforms of calcineurin irrespective of their substrates or activation mechanisms. J Biochem 113:292-298
171. Jin L, Harrison SC (2002) Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci USA 99:13522-13526
172. Huai Q, Kim HY, Liu Y, Zhao Y, Mondragon A, Liu JO, Ke H (2002) Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci USA 99:12037-12042
173. Stoddard BL, Flick KE (1996) Calcineurin-immunosuppressor complexes. Curr Opin Struct Biol 6:770-775
174. Rusnak F, Mertz P (2000) Calcineurin: form and function. Physiol Rev 80:1483-1521
175. Musson RE, Smit NP (2011) Regulatory mechanisms of calcineurin phosphatase activity. Curr Med Chem 18:301-315
176. Baughman G, Wiederrecht GJ, Campbell NF, Martin MM, Bourgeois S (1995) FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol Cell Biol 15:4395-4402
177. Weiwad M, Edlich F, Kilka S, Erdmann F, Jarczowski F, Dorn M, Moutty MC, Fischer G (2006) Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry 45:15776-15784
178. Cardenas ME, Hemenway C, Muir RS, Ye R, Fiorentino D, Heitman J (1994) Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. EMBO J 13:5944-5957
179. Aramburu J, Yaffe MB, Lopez-Rodriguez C, Cantley LC, Hogan PG, Rao A (1999) Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285:2129-2133
180. Park S, Uesugi M, Verdine GL (2000) A second calcineurin binding site on the NFAT regulatory domain. Proc Natl Acad Sci USA 97:7130-7135
181. Li H, Zhang L, Rao A, Harrison SC, Hogan PG (2007) Structure of calcineurin in complex with PVIVIT peptide: portrait of a low-affinity signalling interaction. J Mol Biol 369:1296-1306
182. Rodriguez A, Roy J, Martinez-Martinez S, Lopez-Maderuelo MD, Nino-Moreno P, Orti L, Pantoja-Uceda D, Pineda-Lucena A, Cyert MS, Redondo JM (2009) A conserved docking surface on calcineurin mediates interaction with substrates and immunosuppressants. Mol Cell 33:616-626
183. Takeuchi K, Roehrl MH, Sun ZY, Wagner G (2007) Structure of the calcineurin-NFAT complex: defining a T cell activation switch using solution NMR and crystal coordinates. Structure 15:587-597
184. Roehrl MH, Wang JY, Wagner G (2004) Discovery of small-molecule inhibitors of the NFAT-calcineurin interaction by competitive high-throughput fluorescence polarization screening. Biochemistry 43:16067-16075
185. Roehrl MH, Kang S, Aramburu J, Wagner G, Rao A, Hogan PG (2004) Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc Natl Acad Sci USA 101:7554-7559
186. (2+)- calcineurin-NFAT signaling. Nat Struct Mol Biol 19:337-345
187. Huang GN, Huso DL, Bouyain S, Tu J, McCorkell KA, May MJ, Zhu Y, Lutz M, Collins S, Dehoff M, Kang S, Whartenby K, Powell J, Leahy D, Worley PF (2008) NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science 319:476-481
188. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10:457-468
189. Jacinto E, Hall MN (2003) Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4:117-126
190. Hoeffer CA, Tang W, Wong H, Santillan A, Patterson RJ, Martinez LA, Tejada-Simon MV, Paylor R, Hamilton SL, Klann E (2008) Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron 60:832-845
191. Cimprich KA, Shin TB, Keith CT, Schreiber SL (1996) cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein. Proc Natl Acad Sci USA 93:2850-2855
192. Liang J, Choi J, Clardy J (1999) Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 Å resolution. Acta Crystallogr D Biol Crystallogr 55(Pt 4):736-744
193. Kallen J, Sedrani R, Cottens S (1996) X-ray crystal structure of 28-o-methylrapamycin complexed with FKBP12: is the cyclohexyl moiety part of the effector domain of rapamycin? J Am Chem Soc 118:5857-5861
194. Sedrani R, Cottens S, Kallen J, Schuler W (1998) Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 30:2192-2194
195. Graziani EI (2009) Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs. Nat Prod Rep 26:602-609
196. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284:8023-8032
197. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ (2005) North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304
198. Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K (2008) A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 68:2934-2943
199. Sarkaria JN, Galanis E, Wu W, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Buckner JC (2011) North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 81:468-475
200. Marx SO, Marks AR (2001) Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104:852-855
201. Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, Kang SA, Zhao J, Look AT, Sorger PK, Sabatini DM, Gray NS (2012) Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J Biol Chem 287:9742-9752
202. Liu Q, Kang SA, Thoreen CC, Hur W, Wang J, Chang JW, Markhard A, Zhang J, Sim T, Sabatini DM, Gray NS (2012) Development of ATP-competitive mTOR inhibitors. Methods Mol Biol 821:447-460
203. Chen YW, Smith ML, Sheets M, Ballaron S, Trevillyan JM, Burke SE, Rosenberg T, Henry C, Wagner R, Bauch J, Marsh K, Fey TA, Hsieh G, Gauvin D, Mollison KW, Carter GW, Djuric SW (2007) Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J Cardiovasc Pharmacol 49:228-235
204. Force T, Kolaja KL (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 10:111-126
205. Hernlund E, Olofsson MH, Fayad W, Fryknas M, Lesiak-Mieczkowska K, Zhang X, Brnjic S, Schmidt V, D'Arcy P, Sjoblom T, De Milito A, Larsson R, Linder S (2012) The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy. Eur J Cancer 48:396-406
206. Janne PA, Gray N, Settleman J (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8:709-723
207. Clardy J, Walsh C (2004) Lessons from natural molecules. Nature 432:829-837
208. Andexer JN, Kendrew SG, Nur-e-Alam M, Lazos O, Foster TA, Zimmermann AS, Warneck TD, Suthar D, Coates NJ, Koehn FE, Skotnicki JS, Carter GT, Gregory MA, Martin CJ, Moss SJ, Leadlay PF, Wilkinson B (2011) Biosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismate. Proc Natl Acad Sci USA 108:4776-4781
209. Lyons WE, George EB, Dawson TM, Steiner JP, Snyder SH (1994) Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci USA 91:3191-3195
210. Poulter MO, Payne KB, Steiner JP (2004) Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 128:1-6
211. Amit M, Berisio R, Baram D, Harms J, Bashan A, Yonath A (2005) A crevice adjoining the ribosome tunnel: hints for cotranslational folding. FEBS Lett 579:3207-3213
212. Tzellos TG, Kouvelas D (2008) Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol 64:337-341
213. Weiss HM, Fresneau M, Moenius T, Stuetz A, Billich A (2008) Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab Dispos 36:1812-1818
214. Sàrdy M, Ruzicka T, Kuhn A (2009) Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res 301:93-98
215. Plotz SG, Ring J (2010) What's new in atopic eczema? Expert Opin Emerg Drugs 15:249-267
216. Paul E, Thiele E (2008) Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. N Engl J Med 358:190-192
217. Jozwiak J, Jozwiak S, Oldak M (2006) Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment. Med Res Rev 26:160-180
218. Bauriedel G, Jabs A, Kraemer S, Nickenig G, Skowasch D (2008) Neointimal expression of rapamycin receptor FK506-binding protein FKBP12: postinjury animal and human in-stent restenosis tissue characteristics. J Vasc Res 45:173-178
219. Dabora SL, Franz DN, Ashwal S, Sagalowsky A, Dimario FJ Jr, Miles D, Cutler D, Krueger D, Uppot RN, Rabenou R, Camposano S, Paolini J, Fennessy F, Lee N, Woodrum C, Manola J, Garber J, Thiele EA (2011) Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS One 6:e23379
220. Amato R (2011) Everolimus for the treatment of advanced renal cell carcinoma. Expert Opin Pharmacother 12:1143-1155
221. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Said SA, Kleijne MA, Sen H, Lowik MM, van der Palen J, Verhorst PM, de Man FH (2012) A randomized controlled trial in second-Generation Zotarolimus-eluting resolute stents versus Everolimus-eluting xience V stents in real-world patients: the tWENTE trial. J Am Coll Cardiol 59:1350-1361
222. Wang X, Zhan Y, Zhao L, Alvarez J, Chaudhary I, Zhou BB, Abraham RT, Feuerstein GZ (2011) Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development. J Pharmacol Exp Ther 339:421-429
223. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B (2012) Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104:93-113
224. Costanzo MR (2001) New immunosuppressive drugs in heart transplantation. Curr Control Trials Cardiovasc Med 2:45-55
225. Stebbins JL, Zhang Z, Chen J, Wu B, Emdadi A, Williams ME, Cashman J, Pellecchia M (2007) Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors. J Med Chem 50:6607-6617
226. Yamazaki S, Yamaji T, Murai N, Yamamoto H, Price RD, Matsuoka N, Mutoh S (2008) FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. Neuropharmacology 55:1226-1230
227. van Rossum HH, Romijn FP, Smit NP, de Fijter JW, van Pelt J (2009) Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12. Biochem Pharmacol 77:1206-1212
228. Shor B, Gibbons JJ, Abraham RT, Yu K (2009) Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 8:3831-3837
229. Sun F, Li P, Ding Y, Wang L, Bartlam M, Shu C, Shen B, Jiang H, Li S, Rao Z (2003) Design and structure-based study of new potential FKBP12 inhibitors. Biophys J 85:3194-3201
230. Raju R, Piggott AM, Conte M, Tnimov Z, Alexandrov K, Capon RJ (2010) Nocardiopsins: new FKBP12-binding macrolide polyketides from an Australian marine-derived actinomycete, Nocardiopsis sp. Chemistry 16:3194-3200
231. Erdmann F, Weiwad M, Kilka S, Karanik M, Patzel M, Baumgrass R, Liebscher J, Fischer G (2010) The novel calcineurin inhibitor CN585 has potent immunosuppressive properties in stimulated human T cells. J Biol Chem 285:1888-1898
232. Gopalakrishnan R, Kozany C, Gaali S, Kress C, Hoogeland B, Bracher A, Hausch F (2012) Evaluation of synthetic FK506 analogs as ligands for the FK506-binding proteins 51 and 52. J Med Chem 55:4114-4122
233. Gopalakrishnan R, Kozany C, Wang Y, Schneider S, Hoogeland B, Bracher A, Hausch F (2012) Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52. J Med Chem 55:4123-4131
234. Sieber M, Baumgrass R (2009) Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506? Cell Commun Signal 7:25
235. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, Alessi DR (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421:29-42
236. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7(2):e38
237. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, Kim SK, Conant R, Curran K, Kaplan J, Verheijen J, Ayral-Kaloustian S, Mansour TS, Abraham RT, Zask A, Gibbons JJ (2010) Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 70:621-631
238. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16:205-213
239. Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S (2005) Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65:3336-3346
240. Xie J, Herbert TP (2012) The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes. Cell Mol Life Sci 69:1289-1304
241. Jazirehi AR, Wenn PB, Damavand M (2012) Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy. Am J Cancer Res 2:178-191
242. Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA (2012) Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 17:69-95
243. Populo H, Lopes JM, Soares P (2012) The mTOR signalling pathway in human cancer. Int J Mol Sci 13:1886-1918
244. Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn DI (2012) Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther 11:526-537
245. Sundin T, Hentosh P (2012) InTERTesting association between telomerase, mTOR and phytochemicals. Expert Rev Mol Med 14:e8. doi: 10.1017/erm.2012.1
246. Prescott TA, Veitch NC, Simmonds MS (2011) Direct inhibition of calcineurin by caffeoyl phenylethanoid glycosides from Teucrium chamaedrys and Nepeta cataria. J Ethnopharmacol 137:1306-1310
247. Mair W, Morantte I, Rodrigues AP, Manning G, Montminy M, Shaw RJ, Dillin A (2011) Lifespan extension induced by AMPK and calcineurin is mediated by CRTC-1 and CREB. Nature 470:404-408
248. Williams CR, Gooch JL (2012) Calcineurin inhibitors and immunosuppression - a tale of two isoforms. Expert Rev Mol Med 14:e14
249. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, Woods A, Robinson IC, Schuster E, Batterham RL, Kozma SC, Thomas G, Carling D, Okkenhaug K, Thornton JM, Partridge L, Gems D, Withers DJ (2009) Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326:140-144
250. Fontana L, Partridge L, Longo VD (2010) Extending healthy life span - from yeast to humans. Science 328:321-326
251. Blagosklonny MV (2011) Progeria, rapamycin and normal aging: recent breakthrough. Aging (Albany NY) 3:685-691
252. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184-192
253. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21-35
254. Imanishi T, Kobayashi K, Kuki S, Takahashi C, Akasaka T (2006) Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis 189:288-296
255. Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H, Khosla S, Jensen MD, Kirkland JL (2010) Fat tissue, aging, and cellular senescence. Aging Cell 9:667-684
256. Slagboom PE, Beekman M, Passtoors WM, Deelen J, Vaarhorst AA, Boer JM, van den Akker EB, van Heemst D, de Craen AJ, Maier AB, Rozing M, Mooijaart SP, Heijmans BT, Westendorp RG (2011) Genomics of human longevity. Philos Trans R Soc Lond B Biol Sci 366:35-42
257. Watson JM, Riha K (2011) Telomeres, aging, and plants: from weeds to Methuselah - a mini-review. Gerontology 57:129-136
258. Sharp ZD (2011) Aging and TOR: interwoven in the fabric of life. Cell Mol Life Sci 68:587-597
259. Bai X, Jiang Y (2010) Key factors in mTOR regulation. Cell Mol Life Sci 67:239-253
260. [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers. Bioorg Med Chem Lett 22:1569-1574
261. Das BB, Shoemaker L, Subramanian S, Johnsrude C, Recto M, Austin EH (2007) Acute sirolimus pulmonary toxicity in an infant heart transplant recipient: case report and literature review. J Heart Lung Transplant 26:296-298
262. Yano I (2008) Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors. Drug Metab Pharmacokinet 23:150-157
263. Naesens M, Kuypers DR, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4:481-508
264. Veroux M, Tallarita T, Corona D, D'Assoro A, Gurrieri C, Veroux P (2011) Sirolimus in solid organ transplantation: current therapies and new frontiers. Immunotherapy 3:1487-1497
265. Sommerer C, Zeier M, Czock D, Schnitzler P, Meuer S, Giese T (2011) Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia. Ther Drug Monit 33:373-379
266. De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, Pane F, Heslop HE, Brenner MK, Rooney CM, Savoldo B (2009) Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 114:4784-4791
267. Russell RC, Fang C, Guan KL (2011) An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development 138:3343-3356
268. Castilho RM, Squarize CH, Chodosh LA, Williams BO, Gutkind JS (2009) mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell 5:279-289
269. Yilmaz OH, Katajisto P, Lamming DW, Gultekin Y, Bauer-Rowe KE, Sengupta S, Birsoy K, Dursun A, Yilmaz VO, Selig M, Nielsen GP, Mino-Kenudson M, Zukerberg LR, Bhan AK, Deshpande V, Sabatini DM (2012) mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature 486:490-495
270. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335:1638-1643
271. Li MO, Flavell RA (2008) TGF-β: a master of all T cell trades. Cell 134:392-404
272. Xi Q, Wang Z, Zaromytidou AI, Zhang XH, Chow-Tsang LF, Liu JX, Kim H, Barlas A, Manova-Todorova K, Kaartinen V, Studer L, Mark W, Patel DJ, Massagué J (2011) A poised chromatin platform for TGF-β access to master regulators. Cell 147:1511-1524
273. Albinana V, Sanz-Rodriguez F, Recio-Poveda L, Bernabeu C, Botella LM (2011) Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-β1 signaling in endothelial cells. Mol Pharmacol 79:833-843
274. Chaikuad A, Alfano I, Kerr G, Sanvitale CE, Boergermann JH, Triffitt JT, von Delft F, Knapp S, Knaus P, Bullock AN (2012) Structure of the BMP receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem. PMID: 22977237
275. Liu D, McIlvain HB, Fennell M, Dunlop J, Wood A, Zaleska MM, Graziani EI, Pong K (2007) Screening of immunophilin ligands by quantitative analysis of neurofilament expression and neurite outgrowth in cultured neurons and cells. J Neurosci Methods 163:310-320
276. Ruan B, Pong K, Jow F, Bowlby M, Crozier RA, Liu D, Liang S, Chen Y, Mercado ML, Feng X, Bennett F, von Schack D, McDonald L, Zaleska MM, Wood A, Reinhart PH, Magolda RL, Skotnicki J, Pangalos MN, Koehn FE, Carter GT, Abou-Gharbia M, Graziani EI (2008) Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci USA 105:33-38
277. Kuffler DP (2009) Enhancement of nerve regeneration and recovery by immunosuppressive agents. Int Rev Neurobiol 87:347-862
278. Toll EC, Seifalian AM, Birchall MA (2011) The role of immunophilin ligands in nerve regeneration. Regen Med 6:635-652